Nurix Therapeutics

Nurix Develops Small Molecule Inhibitors for the Treatment of Proliferative and Degenerative Diseases. The UPS is a regulatory pathway that directs protein degradation, a function essential for cellular health, offering therapeutic opportunities across multiple disease areas, including oncology. Nurix’s proprietary product engine leverages deep mechanistic insights into the UPS to deliver potent small molecule drug candidates with the potential to make a significant impact on patients.Nurix has two complementary proprietary ubiquitin/E3 ubiquitin ligase platforms: the “Chimeric Targeting Molecule Platform,” which harnesses the body’s natural protein recycling system to degrade disease-causing proteins, and the “E3 Ubiquitin Ligase Inhibitor” platform, which inhibits E3 ubiquitin ligases, disrupting the body’s natural protein recycling system and thereby increasing target protein levels.The company’s primary focus is on developing cancer therapeutics, including novel small-molecule immuno-oncology drugs.